The estimated Net Worth of Naseem Amin is at least $139 ezer dollars as of 25 January 2019. Naseem Amin owns over 571,429 units of Bellerophon Therapeutics Inc stock worth over $72,755 and over the last 9 years he sold BLPH stock worth over $0. In addition, he makes $66,324 as Independent Director at Bellerophon Therapeutics Inc.
Naseem has made over 1 trades of the Bellerophon Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 571,429 units of BLPH stock worth $400,000 on 25 January 2019.
The largest trade he's ever made was buying 571,429 units of Bellerophon Therapeutics Inc stock on 25 January 2019 worth over $400,000. On average, Naseem trades about 30,075 units every 0 days since 2015. As of 25 January 2019 he still owns at least 1,818,867 units of Bellerophon Therapeutics Inc stock.
You can see the complete history of Naseem Amin stock trades at the bottom of the page.
Dr. Naseem Amin M.D. serves as Independent Director of the Company. Dr. Amin has served as the Chief Executive Officer at GMP-Orphan since June 2017 and has served as the Chairman of Arix Bioscience plc, a global venture capital company focused on investing in life sciences, since April 2020. Dr. Amin had served as the Chief Scientific Officer of Smith and Nephew Plc until 2014. Previously, Dr. Amin was Senior Vice President, Business Development at Biogen Idec from 2005 to 2009 and was with Genzyme Corporation from 1999 to 2005, most recently as Head, International Business Development and where he has also led the clinical development of five currently marketed therapeutic products. Dr. Amin began his career at Baxter Healthcare Corporation, where he served as Director, Medical Marketing and Portfolio Strategy, Renal Division. Dr. Amin is a Venture Partner at Advent Life Sciences, serves as an Advisory Board member for Imperial College, Department of Biomedical Engineering, and serves as Chairman of OPEN-London, a non-profit organization focused on encouraging and mentoring South Asians from Pakistan who are interested in starting entrepreneurial companies. Dr. Amin received his medical degree from the Royal Free School of Medicine, London, and an MBA from the Kellogg Graduate School of Management, Northwestern University. Amin is qualified to serve on our Board because of his broad industry experience in the Biotech and Medical Device industry.
As the Independent Director of Bellerophon Therapeutics Inc, the total compensation of Naseem Amin at Bellerophon Therapeutics Inc is $66,324. There are 8 executives at Bellerophon Therapeutics Inc getting paid more, with Fabian Tenenbaum having the highest compensation of $1,400,000.
Naseem Amin is 58, he's been the Independent Director of Bellerophon Therapeutics Inc since 2015. There are 5 older and 11 younger executives at Bellerophon Therapeutics Inc. The oldest executive at Bellerophon Therapeutics Inc is Peter Fernandes M. Pharm, 66, who is the Interim Principal Exec. Officer, Chief Regulatory & Safety Officer.
Naseem's mailing address filed with the SEC is C/O AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN 2, L2, D02 T380.
Over the last 10 years, insiders at Bellerophon Therapeutics Inc have traded over $8,853,497 worth of Bellerophon Therapeutics Inc stock and bought 9,412,012 units worth $57,370,250 . The most active insiders traders include Robert Nelsen, Adam Weinstein és Associates Iv L P Venrock H.... On average, Bellerophon Therapeutics Inc executives and independent directors trade stock every 61 days with the average trade being worth of $10,679. The most recent stock trade was executed by Capital Management Lp Puiss... on 13 October 2023, trading 1,076,841 units of BLPH stock currently worth $107,684.
bellerophon therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases. our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.
Bellerophon Therapeutics Inc executives and other stock owners filed with the SEC include: